Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Nice uptick
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Comment by Mole101on Mar 15, 2021 6:19pm
198 Views
Post# 32804245

RE:RE:Nice uptick

RE:RE:Nice uptick
 
From:  To:  


818,528 ($256,641) AGN.CN shares exchanged hands today.

House  Bought  Sold  Net 
House 080
National Bank
Bought $76,954
Volume 243,500
Average $0.316
Sold $13,887
Volume 45,000
Average $0.309
Net $63,067
Volume 198,500
 
House 001
Anonymous
Bought $121,412
Volume 388,303
Average $0.313
Sold $77,973
Volume 249,500
Average $0.313
Net $43,439
Volume 138,803
 
House 014
ITG
Bought $6,299
Volume 20,000
Average $0.315
Sold 0
Volume 0
Average 0
Net $6,299
Volume 20,000
 
House 017
Integral
Bought $1,525
Volume 5,000
Average $0.305
Sold 0
Volume 0
Average 0
Net $1,525




quote=Danorrn]SMIO is positive, MACD is positive and the trend is your friend. Up on the daily and weekly chart.[/quote]
 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities